基本信息
views: 32
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr Montse Sanchez-Cespedes graduated in Biology and obtained her PhD in Genetics and Molecular Biology from the Universidad de Barcelona in Spain. From 1997 to 2001 she was a Postdoctoral Fellow at The Johns Hopkins University School of Medicine, Baltimore-USA. Dr Sanchez-Cespedes focused on the identification of novel genetic and molecular alterations in lung cancer. During this period, she discovered that LKB1 was genetically inactivated in lung adenocarcinomas. Today this is a well-established tumor suppressor gene involved in lung cancer development. After that, she was the group leader first, at the Spanish National Cancer Centre (CNIO) in Madrid, Spain (until 2008) and later at the Bellvitge Biomedical Research Institute-IDIBELL in Barcelona, Spain (until 2019). Now, she leads the Cancer Genetics Group at the Josep Carreras Research Institute in Badalona, Barcelona, Spain.
Over all these years, her group has made important contributions to the dissection and identification of gene alterations and expression profiles in lung cancer. These include, among others, the discovery of genetic inactivation of SMARCA4 (also BRG1), coding the ATPase of the SWI/SNF chromatin remodelling complex, and of MAX, binding partner of the MYC oncoprotein, in small cell lung cancer.
The laboratory of Dr Sanchez-Cespedes laboratory is devoted to the genetic and molecular study of the mechanisms that drive cancer development. The group uses the latest high throughput sequencing technologies to create profiles and catalogues of the recurrently altered genes in cancer. Further, we are actively investigating the mechanistics that underlie the inactivation of SMARCA4 and the des-regulation of the MYC/MAX network contribution to cancer development. Finally, through collaborations with clinicians and pathologists within our network of nearby hospitals, we pursue the identification and characterization of genetic and molecular features that predict response to novel therapeutics. Ultimately, our purpose is to implement the clinical management of cancer patients and to design novel therapeutic strategies.
Research Interests
Papers共 198 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
LUNG CANCER (2024): 107502-107502
crossref(2023)
crossref(2023)
crossref(2023)
crossref(2023)
crossref(2023)
Chiara Ambrogio,Francisco J. Carmona,August Vidal,Mattia Falcone,Patricia Nieto,Octavio A. Romero,Sara Puertas,Miguel Vizoso, Ernest Nadal,Teresa Poggio,Montserrat Sánchez-Céspedes, Manel Esteller,
crossref(2023)
Juan J. Alburquerque-Bejar, Pablo Navajas-Chocarro,Maria Saigi, Ana Ferrero-Andres, Juan M. Morillas,Andrea Vilarrubi,Antonio Gomez,José L. Mate,Ana M. Munoz-Marmol,Octavio A. Romero,Pedro Blecua,Veronica Davalos,
Cell Reports Medicineno. 4 (2023): 101006-101006
crossref(2023)
Chiara Ambrogio,Francisco J. Carmona,August Vidal,Mattia Falcone,Patricia Nieto,Octavio A. Romero,Sara Puertas,Miguel Vizoso, Ernest Nadal,Teresa Poggio,Montserrat Sánchez-Céspedes, Manel Esteller,
crossref(2023)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn